Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole brain radiotherapy with or without vandetanib for melanoma brain metastases
2011-000661-12Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vandetanib in melanoma and brain metastases (2 arms), sponsored by University of Oxford. Primary endpoint: Progression-free survival in the brain. Started Jul 2011; status: completed.
02
Drugs
vandetanib
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on 2011-000661-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000661-12.